M. J. Drake Et Al. , "Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)," INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.71, no.5, 2017
Drake, M. J. Et Al. 2017. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.71, no.5 .
Drake, M. J., MacDiarmid, S., Chapple, C. R., ESEN, A. A., Athanasiou, S., Cambronero Santos, J., ... Mitcheson, D.(2017). Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.71, no.5.
Drake, Marcus Et Al. "Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)," INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.71, no.5, 2017
Drake, Marcus J. Et Al. "Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)." INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.71, no.5, 2017
Drake, M. J. Et Al. (2017) . "Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)." INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , vol.71, no.5.
@article{article, author={Marcus J. Drake Et Al. }, title={Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)}, journal={INTERNATIONAL JOURNAL OF CLINICAL PRACTICE}, year=2017}